Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

- Company Posts Record Quarterly EPS of $0.58, 45% Above Prior Year, Based

on Positive Operating Results and One-Time Legal Benefit - - Total Revenues Increase 21% to Establish Quarterly Record of $122.6

Million, Product Sales Rise 16% to All-Time High of $101.5 Million - - For 2008, Company Now Expects EPS of $1.72 to $1.76, Total Revenues of

$450 to $455 Million -

SAN DIEGO, April 28 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported strong financial results for the first quarter of 2008 and raised its full-year guidance for earnings per share (EPS) and total revenues.

"Gen-Probe posted excellent financial results in the first quarter of 2008, as new records in both clinical diagnostics and blood screening enabled us to exceed $100 million in quarterly product sales for the first time," said Henry L. Nordhoff, the Company's chairman and chief executive officer. "We also established new all-time highs for total revenue and net income, and made important progress in our PROCLEIX(R) ULTRIO(R), human papillomavirus (HPV) and prostate cancer development programs."

In the first quarter of 2008, product sales were $101.5 million, compared to $87.2 million in the prior year period, an increase of 16%. Total revenues for the first quarter of 2008 were $122.6 million, compared to $101.1 million in the prior year period, an increase of 21%. Net income was $31.9 million ($0.58 per share) in the first quarter of 2008, compared to $21.5 million ($0.40 per share) in the prior year period, an increase of 48% (45% per share). In this press release, all per share amounts are calculated on a fully diluted basis, and all results are presented on a US GAAP basis
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These ... through the activities in the soil or in the ... the stress on reducing environmental pollution and on reducing ... and segments the bio fertilizers market with analysis and ...
(Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... 2011 Cross reference:   Picture ... be downloaded free of charge at:   http://www.presseportal.de/pm/18701/eppendorf-ag?keygroup=bild ... Science from 2008, Dr. Andrew Holt and ... how chemicals used as manufacturing additives can substantially inhibit ...
... HANOVER, N.J., Dec. 2, 2011 Novartis Pharmaceuticals Corporation ... presentations on data from its robust oncology portfolio at ... for patients with cancers and hematological diseases. ... held from December 6-10, will feature data presentations from ...
... Ltd. - (OTCBB: HADSY), a publicly traded portfolio of ... owned by the Hadassah University Hospital, Israel,s foremost medical ... companies have received grant approvals from the Israeli Office ... Industry, Trade and Labor. These approvals ...
Cached Biology Technology:Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 3Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 4Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 5Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 6Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 7Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 8Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 9Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 10Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 11Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 12Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 13Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 14Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 15Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 16Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 17Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 18Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 19Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 20Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 21Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... offering. One major trend emerging in ... in technology, it is important to upgrade biometric solutions ...
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need to sign ... key or the answer to your secret question. What,s your dog,s ... Hoyos Labs , a digital infrastructure security company, launches ... frustration that comes with usernames, passwords and PINs – 1U ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... by scientists at the University of York and Yunnan ... management of cattle populations in northern China, around the ... East, over 10,000 years ago., The domestication of cattle ... researchers believed that humans started domesticating cattle around 10,000 ...
... Fortune has studied glass knifefish, a species of three-inch long ... laboratory he tries to understand how their tiny brains control ... intrigued by the special "ribbon fin" that knifefish use to ... allowing the fish to move forward or backward. Biologists have ...
... researchers says in a new paper that climate science ... practical applications for dealing with the myriad impacts of ... does much of the organizational structure, they say, to ... snowpack, to severe storms, to sea level rise. What ...
Cached Biology News:Researchers uncover origins of cattle farming in China 2A fish that pushes in the wrong direction solves a mystery of animal locomotion 2A fish that pushes in the wrong direction solves a mystery of animal locomotion 3Researchers advocate for climate adaptation science 2Researchers advocate for climate adaptation science 3
... from an inert polymer with a unique split ... split septum caps for use with 384-well tall-chimney ... when used in conjunction with screw or clip-down ... pipetting equipment 384 septum caps may be ...
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
... The SearchLight® IR Mouse Cytokine Array ... assay) for the quantitative measurement of 12 ... plasma and culture supernatants. Each well of ... that capture specific cytokines in standards and ...
Biology Products: